Gene-targeted therapy for tumors refers to targeting the signature molecules of tumor cells and preventing the process of cancerous transformation of cells, so as to achieve the purpose of treating tumors. Targeted drugs can play a role by interfering with cell cycle, inducing differentiation of tumor cells, inducing apoptosis of tumor cells, inhibiting tumor angiogenesis, inhibiting proliferation of tumor cells, inhibiting metastasis of tumor cells and other pathways. Some targeted drugs can be applied to certain tumors alone. For patients with chronic granulocytic leukemia, if they are treated with imatinib, their complete hematological remission rate can reach 96.6%, and the effective rate of imatinib for gastrointestinal mesenchymal tumors ineffective with conventional chemotherapy is 37%. Targeted agents can be used in combination with chemotherapy and radiotherapy. The combination of targeted drugs and chemotherapy is currently the main way of clinical application of monoclonal antibodies and anti-tumor angiogenesis drugs. Molecular targeted drugs can enhance the sensitivity of tumor cells to radiotherapy and increase the effect of radiotherapy. Targeted drugs are highly targeted and have fewer adverse reactions, but the treatment plan for tumor patients should be decided by doctors, and it is recommended that patients should consult doctors in time.